

## Special Issue

# Hepatitis B Virus: Its Life Cycle and the Therapeutic Targets

### Message from the Guest Editor

We do not have many or good options to save the lives of HBV-infected people around the world. Finding NTCP (sodium taurocholate co-transporting peptide) has enabled us to analyze the HBV life cycle in vitro using human hepatoma cell lines, though it may not be enough. Much knowledge of the HBV life cycle has been accumulating, and thus it is time to think of the next generation of HBV therapy. This Special Issue will accept all kinds of manuscripts (reviews, research articles, and short communications). Based on the HBV life cycle, what kind of therapy will be designed? What factors could be targets for HBV treatment? Conceptual ideas on HBV treatment and analyses on new compounds to act on cellular targets are also of interest. We would like to discuss the future of HBV treatment, with a view to conquering the infection.

---

### Guest Editor

Prof. Dr. Keiji Ueda

Division of Virology, Department of Microbiology and Immunology,  
Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita,  
Osaka 565-0871, Japan

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/67619](https://mdpi.com/si/67619)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[viruses](https://viruses)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).